title: Oral and subcutaneous therapy of canine atopic dermatitis with recombinant feline interferon omega.
abstract: Canine atopic dermatitis (CAD) is a common allergic skin disease that has been treated with subcutaneously administered interferons (IFN). Recombinant feline IFN-ω (rFeIFN-ω) was reported to be efficacious for CAD. Whether dogs develop neutralizing antibodies against rFeIFN-ω during long-term treatment and whether orally administered IFNs are efficacious in CAD is unknown. The aim of this study was to evaluate the potential development of antibodies against rFeIFN-ω in atopic dogs and to compare subcutaneous and oral IFN therapy. Twenty-six atopic dogs were randomly assigned to two groups. The first group (n=15) received eight subcutaneous injections of rFeIFN-ω (Virbagen® omega, Virbac, Carros, France) over four months, the second group (n=11) received rFeIFN-ω daily orally. Concurrent medication was permitted, except systemically acting glucocorticoids and cyclosporin, which had to be withdrawn at least two weeks prior to the study. Serum samples for antibody detection were collected before and after the study. On days 0, 60 and 120 skin lesions and pruritus were evaluated using a validated lesion score (Canine Atopic Dermatitis Extent and Severity Index=CADESI) and a validated pruritus score. Concurrent medications were recorded. For every visit a total score, consisting of CADESI, pruritus score and medication score was created. For antibody detection an indirect ELISA, using Virbagen® omega as antigen, was performed. Comparison of pruritus scores, CADESI and total scores between days 0 and 120 showed improvement in both groups, however, significant improvement could only be detected in the oral group with CADESI and total scores (61%, P=0.04 and 36%, P=0.02 respectively). Serum antibodies against rFeIFN-ω could not be detected in any of the dogs. In this study antibody production could not be demonstrated. It suggests better efficacy with oral IFN administration, which should be further verified in larger, randomized, controlled studies.
authors.affiliation: Centre for Clinical Veterinary Medicine, Ludwig Maximilian University Munich, Veterinaerstr. 13, 80539 Munich, Germany. Electronic address: petralit@gmx.de.
authors.forename: Petra
authors.initials: P
authors.lastname: Litzlbauer
authors.affiliation: Centre for Clinical Veterinary Medicine, Ludwig Maximilian University Munich, Veterinaerstr. 13, 80539 Munich, Germany. Electronic address: k.weber@medizinische-kleintierklinik.de.
authors.forename: Karin
authors.initials: K
authors.lastname: Weber
authors.affiliation: Centre for Clinical Veterinary Medicine, Ludwig Maximilian University Munich, Veterinaerstr. 13, 80539 Munich, Germany. Electronic address: R.Mueller@lmu.de.
authors.forename: Ralf S
authors.initials: RS
authors.lastname: Mueller
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002415:Cats; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D007279:Injections, Subcutaneous; D007370:Interferon Type I / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D013058:Mass Spectrometry; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use*; D034421:Sus scrofa
chemical_list: D007370:Interferon Type I; D011994:Recombinant Proteins; C063743:interferon omega 1
keywords: Atopy; Dog; Immune response; Treatment